Anlotinib-induced renal thrombotic microangiopathy

VernacularTitle:安罗替尼致肾脏血栓性微血管病
Author: Yueyi ZHANG ¹ ; Wenling YE ; Mingxi LI ; Wei YE ; Yubing WEN ; Ke ZHENG ; Xuemei LI ; Sanxi AI
Author Information

1. 中国医学科学院北京协和医学院北京协和医院内科，北京　100730
Publication Type:Journal Article
Keywords: Antineoplastic agents; Thrombotic microangiopathies; Anlotinib
From: Adverse Drug Reactions Journal 2021;23(9):497-499
CountryChina
Language:Chinese
Abstract: A 64-year-old female patient received postoperative adjuvant chemotherapy with oxaliplatin and capecitabine after radical resection of rectal cancer for rectal adenocarcinoma with multiple lung metastases. Due to poor therapeutic effect, the patient was switched to anlotinib treatment at a dose of 12 mg/d orally for 2 weeks with a 1-week break and 3 weeks was one cycle. During the second cycle of anlotinib treatment, the patient developed edema, proteinuria, hypertension, and hypoalbuminemia, with normal serum creatinine. The renal pathology suggested renal thrombotic microangiopathy, which was in line with the clinical and pathological manifestations of drug-related renal injury due to anti-vascular endothelial growth factor. After discontinuation of anlotinib and receiving symptomatic treatment such as blood pressure control, the edema gradually subsided along with remission of proteinuria. Three months later, the patient had no proteinuria and the serum albumin was normal.